Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (Nasdaq: VIR) announced the first patient dosed in a Phase 1 dose-expansion cohort evaluating VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer (NCT05997615) on April 13, 2026.
The monotherapy expansion in late-line mCRPC will test a selected Q3W 800/2000/3500 µg/kg step-up dosing after Phase 1 dose-escalation data showed a favorable safety profile and promising anti-tumor activity presented at ASCO in February 2026. Combination expansion cohorts with an ARPI are expected to dose in the coming months ahead of planned pivotal Phase 3 trials in 2027.
Vir Biotechnology (Nasdaq: VIR) said management will participate in three investor conferences in March 2026: TD Cowen (fireside chat Mar 2, 3:10 p.m. ET), Leerink Partners (fireside chat Mar 10, 1:40 p.m. ET), and Barclays (one-on-one meetings Mar 12).
Live webcasts of the fireside chats will be available at the company investor website and archived for 30 days.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) announced a proposed underwritten public offering of $200,000,000 of common stock, with a 30-day underwriter option to purchase up to an additional $30,000,000 of shares. All shares will be offered by Vir and the offering is subject to market conditions and SEC filings.
Goldman Sachs, Leerink Partners, Evercore ISI and Barclays are book-running managers. The shares are being offered under an automatically effective Form S-3 registration filed November 3, 2023.
Vir Biotechnology (Nasdaq: VIR) reported Q4 and full-year 2025 results and provided a corporate update on Feb 23, 2026. Key developments include a global collaboration with Astellas for PSMA-targeted TCE VIR-5500, updated Phase 1 VIR-5500 data showing favorable safety and anti-tumor activity, and $781.6 million in cash and investments as of Dec 31, 2025.
Pipeline and commercial moves include a Norgine license for tobevibart+elebsiran in select regions and upcoming Phase 3 plans for VIR-5500 in 2027.
Vir Biotechnology (Nasdaq: VIR) reported updated Phase 1 dose-escalation results for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager in metastatic castration-resistant prostate cancer (mCRPC).
In 58 monotherapy patients there were no dose-limiting toxicities, manageable Grade ≥3 treatment-related adverse events in 12% (7/58), dose-dependent anti-tumor activity in ≥3,000 µg/kg cohorts (PSA50 82%, PSA90 53%) and RECIST objective responses of 45% (5/11); registrational trial planned for 2027.
Vir Biotechnology (Nasdaq: VIR) and Astellas (TSE: 4503) entered a global collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer.
Vir will receive $335M upfront/near-term, share U.S. profits 50/50, and may receive up to $1.37B additional milestones; Astellas leads U.S. commercialization and holds ex-U.S. exclusive rights. Global development costs split 60/40 (Astellas/Vir). Closing is subject to customary conditions including HSR clearance.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Monday, February 23, 2026 at 5:30 p.m. ET / 2:30 p.m. PT to provide a corporate update and discuss fourth-quarter and full-year financial results for the period ended December 31, 2025.
According to the company, the call can be accessed via the Events & Presentations page on Vir Biotechnology's website.
Vir Biotechnology (Nasdaq: VIR) reported positive Phase 2 SOLSTICE results in chronic hepatitis delta showing undetectable HDV RNA (TND) in 88% of combination tobevibart + elebsiran participants evaluated at Week 96 versus 46% with antibody monotherapy at Week 96. No treatment-related Grade ≥3 adverse events were observed in the combination arm. The registrational ECLIPSE program is fully enrolled (ECLIPSE 1 and 3) with ECLIPSE 1 topline expected in Q4 2026 and ECLIPSE 2/3 toplines in Q1 2027. Vir will present Phase 1 VIR-5500 data at ASCO GU 2026. Year-end cash and investments were ~$781M, with runway into Q4 2027 after the Norgine licensing agreement.
Vir Biotechnology (NASDAQ: VIR) announced that CEO Marianne De Backer will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast will be available under Events & Presentations in the company's Investors section and the webcast will be archived for 30 days.